Skip to main content

Dako, Ono Pharmaceutical Working on Potential CDx for Opdivo in NSCLC

NEW YORK (GenomeWeb) – Agilent subsidiary Dako and Ono Pharmaceutical are working together to investigate and advance a diagnostic test that will identify which non-small cell lung cancer patients are likely to respond to Opdivo (nivolumab).

"This test is being investigated for its diagnostic utility," the companies said, in order to identify best responders to Opdivo. The drug works by inhibiting PD-1, a protein that impedes the body's ability to launch an immune attack against cancer cells.

The US Food and Drug Administration in December granted accelerated approval of Opdivo as a treatment for advanced or unresectable melanoma patients who are no longer responding to other drugs. Additionally, Ono also received regulatory approval in Japan for Opdivo for the same indication in July.

In the US, Bristol-Myers Squibb sells Opdivo. BMS holds global development and commercialization rights to Opdivo, except in Japan, South Korea, and Taiwan, where Ono retains all rights for the compound.

In January, BMS announced that an open-label, randomized Phase III trial comparing Opdivo to docetaxel in previously treated advanced squamous cell NSCLC patients showed that Opdivo-treated patients lived longer than those in the comparator arm. The trial was stopped early by an independent data monitoring committee because the trial met its survival endpoint.

Ono and Dako didn't disclose the financial details of the deal.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.